ESC Heart Failure (Feb 2024)

Fibroblast growth factor 23 independently predicts adverse outcomes after an acute coronary syndrome

  • Andrea Kallmeyer,
  • Ana Pello,
  • Ester Cánovas,
  • Álvaro Aceña,
  • María Luisa González‐Casaus,
  • Nieves Tarín,
  • Carmen Cristóbal,
  • Carlos Gutiérrez‐Landaluce,
  • Ana Huelmos,
  • Aida Rodríguez‐Valer,
  • Óscar González‐Lorenzo,
  • Joaquín Alonso,
  • Lorenzo López‐Bescós,
  • Jesús Egido,
  • Ignacio Mahillo,
  • Óscar Lorenzo,
  • José Tuñón

DOI
https://doi.org/10.1002/ehf2.14568
Journal volume & issue
Vol. 11, no. 1
pp. 240 – 250

Abstract

Read online

Abstract Aims Abnormalities of mineral metabolism (MM) have been related to cardiovascular disorders. There are no reports on the prognostic role of MM after an acute coronary syndrome (ACS). We aim to assess the prognostic role of MM after an ACS. Methods and results Plasma levels of components of MM [fibroblast growth factor 23 (FGF23), calcidiol, parathormone, klotho, and phosphate], high‐sensitivity C‐reactive protein, and N‐terminal‐pro‐brain natriuretic peptide were measured in 1190 patients at discharge from an ACS. The primary outcome was a combination of acute ischaemic events, heart failure (HF) and death. Secondary outcomes were the separate components of the primary outcome. Age was 61.7 ± 12.2 years, and 77.1% were men. Median follow‐up was 5.44 (3.03–7.46) years. Two hundred and ninety‐four patients developed the primary outcome. At multivariable analysis FGF23 (hazard ratio, HR 1.18 [1.08–1.29], P 60 mL/min/1.73 m2. Conclusions FGF23 and other components of MM are independent predictors of HF and death after an ACS. This effect is homogeneous across different subgroups of population, and it is not limited to patients with chronic kidney disease.

Keywords